Pfizer Inc. (NYSE:PFE) Stake Decreased by Strategic Blueprint LLC

Strategic Blueprint LLC trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 11.8% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 46,227 shares of the biopharmaceutical company’s stock after selling 6,162 shares during the quarter. Strategic Blueprint LLC’s holdings in Pfizer were worth $1,338,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Olistico Wealth LLC acquired a new position in shares of Pfizer during the second quarter valued at $25,000. MFA Wealth Advisors LLC bought a new stake in shares of Pfizer during the 2nd quarter worth about $29,000. Quarry LP bought a new stake in shares of Pfizer during the 2nd quarter worth about $31,000. Financial Connections Group Inc. bought a new position in shares of Pfizer in the second quarter valued at approximately $34,000. Finally, ESL Trust Services LLC bought a new position in shares of Pfizer in the first quarter valued at approximately $37,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. UBS Group upped their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Wells Fargo & Company upped their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their price target for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Eight investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $33.58.

Pfizer Trading Down 1.4 %

Pfizer stock opened at $28.47 on Wednesday. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $31.54. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The firm has a market capitalization of $161.33 billion, a price-to-earnings ratio of -61.89, a P/E/G ratio of 0.99 and a beta of 0.67. The company has a 50 day moving average price of $29.07 and a 200 day moving average price of $28.56.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.14. The company had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.67 EPS. Research analysts forecast that Pfizer Inc. will post 2.67 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.90%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently -365.21%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.